CART22-cells

N/A

Report date: 2024/07/06 20:00:06

Base Information

Drug NameCART22-cells
Drug Alias NameCART22-cellsJJO686
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionCD22 modulatorsT lymphocyte replacements
TargetsCD22
Therapy Area/IndicationsLymphoma, B-CellPrecursor T-Cell Lymphoblastic Leukemia-LymphomaPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesNovartis Pharma AgUniversity Of Pennsylvania
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of Pennsylvania
Inactive CompaniesN/A
Active IndicationsLymphoma, B-CellPrecursor T-Cell Lymphoblastic Leukemia-LymphomaPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A